NCT04637282View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Juvenile Neuronal Ceroid Lipofuscinosis
Interventions
DRUG

PLX-200

15 mg/mL oral solution of experimental drug

DRUG

Placebo

Taste and color-matched drug-free solution

Sponsors
All Listed Sponsors
lead

Polaryx Therapeutics, Inc.

INDUSTRY